BO-112 With Pembrolizumab in Unresectable Malignant Melanoma
Clinical trial NCT04570332 · COMPLETED
Trial details
- NCT number
- NCT04570332
- Sponsor
- Highlight Therapeutics
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-30
- Primary completion
- 2023-10-03
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.